These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38706199)

  • 21. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
    Lipton RB; Munjal S; Buse DC; Alam A; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
    Headache; 2019 Sep; 59(8):1310-1323. PubMed ID: 31410844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom.
    Vo P; Fang J; Bilitou A; Laflamme AK; Gupta S
    J Headache Pain; 2018 Sep; 19(1):82. PubMed ID: 30203163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
    Lipton RB; Pozo-Rosich P; Orr SL; Reed ML; Fanning KM; Dabruzzo B; Buse DC
    Headache; 2023; 63(10):1448-1457. PubMed ID: 37795746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
    Buse DC; Armand CE; Charleston L; Reed ML; Fanning KM; Adams AM; Lipton RB
    Headache; 2021 Apr; 61(4):628-641. PubMed ID: 33797078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment.
    Buse DC; Pozo-Rosich P; Dupont-Benjamin L; Balkaran BL; Lee L; Jauregui A; Gandhi P; Parikh M; Reuter U
    J Headache Pain; 2023 Aug; 24(1):115. PubMed ID: 37612633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).
    Blumenfeld AM; Bloudek LM; Becker WJ; Buse DC; Varon SF; Maglinte GA; Wilcox TK; Kawata AK; Lipton RB
    Headache; 2013 Apr; 53(4):644-55. PubMed ID: 23458496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study.
    Diamond S; Bigal ME; Silberstein S; Loder E; Reed M; Lipton RB
    Headache; 2007 Mar; 47(3):355-63. PubMed ID: 17371352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study.
    Matsumori Y; Ueda K; Komori M; Zagar AJ; Kim Y; Jaffe DH; Takeshima T; Hirata K
    Neurol Ther; 2022 Mar; 11(1):205-222. PubMed ID: 34862581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
    Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population-based survey of Americans with frequent migraine and acute medication use: A plain language summary.
    Starling AJ; Cady R; Buse DC; Buzby M; Lenaburg K
    Pain Manag; 2024; 14(7):335-345. PubMed ID: 39292115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
    Lipton RB; Nicholson RA; Reed ML; Araujo AB; Jaffe DH; Faries DE; Buse DC; Shapiro RE; Ashina S; Cambron-Mellott MJ; Rowland JC; Pearlman EM
    Headache; 2022 Feb; 62(2):122-140. PubMed ID: 35076091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study.
    Buse DC; Reed ML; Fanning KM; Bostic R; Dodick DW; Schwedt TJ; Munjal S; Singh P; Lipton RB
    J Headache Pain; 2020 Mar; 21(1):23. PubMed ID: 32122324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underrecognition of migraine-related stigmatizing attitudes and social burden: Results of the OVERCOME Japan study.
    Igarashi H; Komori M; Ueda K; Zagar AJ; Jaffe DH; Matsumori Y; Takeshima T; Hirata K
    Brain Behav; 2024 Jul; 14(7):e3547. PubMed ID: 39054258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.
    Starling AJ; Cady R; Buse DC; Buzby M; Spinale C; Steinberg K; Lenaburg K; Kymes S
    J Headache Pain; 2024 Feb; 25(1):26. PubMed ID: 38408888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
    Starling AJ; Kymes S; Asher D; Soni-Brahmbhatt S; Karnik-Henry M
    BMC Neurol; 2023 Apr; 23(1):158. PubMed ID: 37081405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.
    MacGregor EA; Brandes J; Eikermann A
    Headache; 2003 Jan; 43(1):19-26. PubMed ID: 12864754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.